Form 4: Incyte R&D President Exercises Options, Sells Shares

Incyte Corp's President of R&D, Pablo J. Cagnoni, exercised stock options and subsequently sold a portion of common stock on March 17, 2026, under a Rule 10b5-1 plan.

Summary

• Pablo J. Cagnoni, President, R&D of Incyte Corp (INCY), engaged in transactions on March 17, 2026.
• Exercised employee stock options to acquire 7,166 shares of common stock at $61.18 per share.
• Exercised employee stock options to acquire 11,501 shares of common stock at $64.25 per share.
• Sold 18,667 shares of common stock at $94.24 per share.
• The transactions were conducted under a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
• Following these transactions, Cagnoni directly owns 234,800 shares of common stock, which includes 229,661 unvested restricted stock units and earned performance stock units.
• Remaining unexercised options include 9,102 shares with an exercise price of $61.18 and 32,910 shares with an exercise price of $64.25.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The insider realized a profit from exercising options, which is a positive for the individual, and the transaction was pre-planned, reducing concerns about market timing.

Positives

• The sale price of $94.24 per share is significantly higher than the exercise prices of $61.18 and $64.25, indicating a profitable transaction for the insider.
• The transactions were executed under a Rule 10b5-1 plan, suggesting a pre-planned sale rather than a reaction to immediate market conditions, which can mitigate concerns about insider sentiment.

Negatives

• An insider sale, even if pre-planned, reduces the insider's direct equity stake and can sometimes be perceived neutrally to slightly negatively by the market, depending on context and scale.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common for executives managing their personal portfolios and compensation. While a sale reduces direct ownership, the pre-planned nature often mitigates concerns about immediate negative sentiment regarding the company's prospects.

Stakeholder Impact

• Shareholders: The sale by a key executive could be interpreted in various ways, but the Rule 10b5-1 plan suggests it is not a reaction to new negative information. The executive still retains a significant beneficial ownership, including unvested units, indicating continued alignment with shareholder interests.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• Remaining options at $61.18 will continue to vest monthly over three years, with the first 25% having vested on July 14, 2024.
• Remaining options at $64.25 will continue to vest monthly over three years, with the first 25% vesting after one year from July 15, 2024.

Key Dates

Recommendation

The filing details a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. This type of transaction is common for executives managing their compensation and personal finances and does not typically signal a change in the company's fundamental outlook. While the insider realized a profit, the overall impact on the company's valuation or future prospects is neutral, warranting a 'hold' recommendation based solely on this filing.

Keywords

Incyte Corp, INCY, Form 4, Insider Trading, Stock Options, Equity Sale, Pablo J. Cagnoni, Rule 10b5-1, Executive Compensation